

02-24-03



CASE 10047 NP

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 305485560 US  
Express Mail Label Number

February 23, 2004  
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

CARBONI ET AL.

APPLICATION NO: 10/677,067

FILED: OCTOBER 1, 2003

FOR: SYNERGISTIC METHODS AND COMPOSITIONS FOR TREATING  
CANCER

Mail Stop DD  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.


In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
(609) 252-3453



---

Maureen S. Gibbons  
Attorney for Applicants  
Reg. No. 44,121

Date: February 23, 2004

FORM PTO-1449  
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
10047 NP  
APPLICATION NO.  
10/677,067  
APPLICANT  
CARBONI ET AL.  
FILING DATE  
OCTOBER 1, 2003

Group



## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	6,337,338	1/8/02	Kozlowski et al.			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AH	WO 03/048133	6/12/03	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AI	WO 01/25220	4/12/01	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AJ	WO 00/35455	6/22/00	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AK	WO 02/102804	12/27/02	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AL	WO 02/092599	11/21/02	PCT			<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AM	Lu, Y., et al., "Insulin-like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)", Journal of the National Cancer Institute, Vol. 93, No. 24, pp. 1852-1857 (2001)
	AN	Normanno, N., et al., "Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth", Annals of Oncology 13, pp. 65-72 (2002)
	AO	Werner, H., et al., "The IGF-I Receptor Gene: A Molecular Target for Disrupted Transcription Factors", Genes, Chromosomes & Cancer, Vol. 36, pp. 113-120 (2003)
	AP	Lu, D., et al., "Simultaneous Blockade of Both the Epidermal Growth Factor Receptor and the Insulin-like Growth Factor Receptor Signaling Pathways in Cancer Cells with a Fully Human Recombinant Bispecific Antibody", The Journal of Biological Chemistry, Vol. 279, No. 4, pp. 2856-2865 (2004)
	AQ	Grothey, A., et al., "The role of insulin-like growth factor I and its receptor in cell growth, transformation, apoptosis, and chemoresistance in solid tumors", J. Cancer Res. Clin. Oncol., Vol. 125, pp. 166-173 (1999)
	AR	Camirand, A., et al., "Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells", Med. Sci. Monit., Vol. 8, No. 12, pp. BR521-BR526 (2002)

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449  
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.  
10047 NP  
APPLICATION NO.  
10/677,067  
APPLICANT  
CARBONI ET AL.  
FILING DATE  
OCTOBER 1, 2003

Group

**U.S. PATENT APPLICATION DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AS	U.S. Patent Appln. No. 10/676,214 (BMS Docket No. LD0318NP)	Filed 10/1/03	Carboni, et al.			
	AT	U.S. Patent Appln. No. 10/674,098 (BMS Docket No. LD0314NP)	Filed 9/29/03	Velaparthi, et al.			
	AU	U.S. Patent Appln. No. 10/263,448 (BMS Docket No. LD0227A CIP)	Filed 10/2/02	Wittman, et al.			
	AV	U.S. Patent Appln. No. 10/751,798 (BMS Docket No. LD0313 NP)	Filed 1/5/04	Beaulieu, et al.			
	AW						
	AX						
	AY						
	AZ						

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
	BA	WO 03/024967	3/27/03	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	BB	WO 03/035619	5/1/03	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	BC	WO 03/035616	5/1/03	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	BD	WO 03/018022	3/6/03	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	BE	WO 02/053596	7/11/02	PCT			<input type="checkbox"/>	<input type="checkbox"/>

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

	BF	Traxler, P., "Protein tyrosine kinase inhibitors in cancer treatment", Exp. Opin. Ther. Patents, Vol. 7, pp. 571-588 (1997)
	BG	Ellis, M., et al., "Insulin-like growth factors in human breast cancer", Breast Cancer Research and Treatment, Vol. 52, pp. 175-184 (1998)
	BH	

**EXAMINER****DATE CONSIDERED**

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.